LNA Sante SA (LNA)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 23.50 |
|---|---|
| 52-week range | 22.00 – 36.50 |
| Return, 1 month / 3 months | −17.5% / −34.0% |
| Return, 1 year / 3 years | +5.8% / +20.2% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 29.2% |
| Worst drawdown (1 year) | -36.2% |
| Average daily value traded | 0.19M EUR |
| Dividend yield | 4.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
LNA Sante is a French healthcare company that runs nursing homes and assisted-living residences for elderly people, along with follow-up care and rehabilitation clinics and services that support patients at home. Its customers are mainly older adults needing long-term accommodation and care, plus patients recovering from illness or surgery, and the public health authorities and insurers that fund their care. The company is based in Vertou, near Nantes, and operates facilities across France.
LNA Sante SA trades under the code LNA on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
LNA Sante SA (LNA) trades on the Euronext Paris in France. It last closed at EUR 23.50 on 23 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 293 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.8% and over the last three months it fell 34.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 44 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.5% | ||
| From 52-week high | -35.6% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -34.0% | ||
| 6-month return | -16.5% | ||
| 12-month return, skipping the last month | 28.3% | ||
| Stability (higher is calmer) | 60 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.2% | ||
| Liquidity | 69 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.19M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.0% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +0.4% |
|---|---|
| 1 month | −17.5% |
| 3 months | −34.0% |
| 6 months | −16.5% |
| 1 year | +5.8% |
| 3 years | +20.2% |
| 5 years | −48.1% |
Signals
| 50-day / 200-day average | 29.10 / 29.18 |
|---|---|
| Golden / death cross (60 days) | Death, 0 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.93 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 Jul 2026 | EUR 0.9500 |
| 8 Jul 2025 | EUR 0.6500 |
| 8 Jul 2024 | EUR 0.6000 |
| 6 Jul 2023 | EUR 0.5000 |
| 7 Jul 2022 | EUR 0.4300 |
| 7 Jul 2021 | EUR 0.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.